All In Biotech

Drug Trial Radar · NCT00980746

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jun 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 557 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

557

Actual

Start

Nov 2007

Primary completion

Nov 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Sep 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.

Conditions

  • Painful Diabetic Neuropathy

Interventions

  • Eslicarbazepine acetateDrug

    Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

  • PlaceboDrug

    oral route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible PainTime frame: 17 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.